36,867 Shares in Option Care Health, Inc. (NASDAQ:OPCH) Acquired by Sciencast Management LP

Sciencast Management LP bought a new position in Option Care Health, Inc. (NASDAQ:OPCH) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 36,867 shares of the company’s stock, valued at approximately $855,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Magnetar Financial LLC boosted its holdings in Option Care Health by 23.1% in the fourth quarter. Magnetar Financial LLC now owns 2,350,598 shares of the company’s stock worth $54,534,000 after purchasing an additional 441,265 shares during the last quarter. Xponance Inc. boosted its holdings in Option Care Health by 3.9% in the fourth quarter. Xponance Inc. now owns 25,056 shares of the company’s stock worth $581,000 after purchasing an additional 944 shares during the last quarter. Signaturefd LLC boosted its holdings in Option Care Health by 487.9% in the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company’s stock worth $28,000 after purchasing an additional 1,005 shares during the last quarter. Cibc World Markets Corp purchased a new position in shares of Option Care Health during the 4th quarter worth $373,000. Finally, Madison Investment Advisors LLC purchased a new position in shares of Option Care Health during the 4th quarter worth $4,135,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Price Performance

OPCH stock opened at $34.58 on Friday. The company has a market capitalization of $5.72 billion, a PE ratio of 29.06, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33. The company’s fifty day moving average price is $31.84 and its 200-day moving average price is $28.32. Option Care Health, Inc. has a one year low of $21.39 and a one year high of $34.85. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73.

Insiders Place Their Bets

In other news, insider Michael Bavaro sold 30,996 shares of Option Care Health stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $33.26, for a total value of $1,030,926.96. Following the sale, the insider now directly owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. The trade was a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.64% of the company’s stock.

Analyst Upgrades and Downgrades

OPCH has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their target price on Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and lifted their price objective for the company from $26.00 to $35.00 in a research report on Thursday, January 23rd. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and increased their target price for the stock from $26.00 to $33.00 in a report on Monday, January 13th. Barrington Research raised their target price on shares of Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. Finally, UBS Group started coverage on shares of Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Option Care Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.